PLoS One:卒中后血浆CRP与卒中后疲劳并无相关

2015-12-30 phylis 译 MedSci原创

背景:脑卒中后疲劳是一种常见的、令人痛苦的问题,但很少有关于它的生物学机制的研究较少。这项队列研究是探讨脑卒中后C-反应蛋白(C反应蛋白)与卒中后疲劳的关系。方法:评估患者卒中后1月,6个月及12个月后,疲劳评估量表,卒中后疲劳定义,医院焦虑和抑郁量表,每天步数。收集患者血样,通过标准的CRP免疫测定CRP的水平。由Pearson相关和独立样本t检验判定每一时间点,CRP和疲劳之间的相关性。将抑郁

背景:脑卒中后疲劳是一种常见的、令人痛苦的问题,但关于它的生物学机制的研究较少。这项队列研究是探讨脑卒中后C-反应蛋白(C反应蛋白)与卒中后疲劳的关系。

方法:患者卒中后1月、6个月及12个月后评估疲劳评估量表、卒中后疲劳定义、医院焦虑和抑郁量表、每天步数。收集患者血样,通过标准的CRP免疫测定CRP的水平。由Pearson相关和独立样本t检验判定每一时间点,CRP和疲劳之间的相关性。将抑郁、焦虑和日常步数为协变量,通过多元线性回归分析1月、6月、12月CRP水平是否可以预测疲劳分数。

结果:共有65名患者(平均年龄67岁,65%为男性),1个月61名,6个月49名,12个月41名参与了评估。1个月或12个月,CRP与疲劳分数不相关,但6个月CRP与疲劳分数轻微相关;然而,控制协变量后,这种相关没有显著性。任何时间点上,CRP与卒中后疲劳并不存在,完全意义上的相关。1个月和6个月时,CRP都不是疲劳的预测因子。

结论:卒中患者中CRP与PSF相关的证据不足。需要较大样本量做进一步的研究,并且控制潜在的混杂因素调查两者之间是否存在相关性。

原文出处:

Wu S, Duncan F, et al. Exploratory Cohort Study of Associations between Serum C - Reactive Protein and Fatigue after Stroke. PLoS One. 2015 Nov 24.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789760, encodeId=ca271e8976023, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 15 14:20:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671226, encodeId=a3d216e1226fa, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Jun 05 07:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260820, encodeId=7e151260820bf, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269580, encodeId=f29d1269580f3, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789760, encodeId=ca271e8976023, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 15 14:20:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671226, encodeId=a3d216e1226fa, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Jun 05 07:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260820, encodeId=7e151260820bf, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269580, encodeId=f29d1269580f3, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789760, encodeId=ca271e8976023, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 15 14:20:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671226, encodeId=a3d216e1226fa, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Jun 05 07:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260820, encodeId=7e151260820bf, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269580, encodeId=f29d1269580f3, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=)]
    2016-01-01 tamgche
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789760, encodeId=ca271e8976023, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 15 14:20:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671226, encodeId=a3d216e1226fa, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Jun 05 07:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260820, encodeId=7e151260820bf, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269580, encodeId=f29d1269580f3, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 01 05:20:00 CST 2016, time=2016-01-01, status=1, ipAttribution=)]
    2016-01-01 rebeccajiejie

相关资讯

PLoS One:患者出现溶栓相关的无症状性出血并不会恶化临床预后

目的:溶栓相关的无症状性出血转化(AHT)是否影响的临床预后尚不清楚。要回答这个问题,研究者调查了溶栓相关的AHT是否影响近期和远期预后。方法:所有数据均来自中国急性缺血性脑卒中溶栓治疗的实施和监控记录(TIM-中国)。根据临床和影像学资料将患者被诊断为AHT组和非出血性转化(HT)的组。排除症状性出血性转化的患者。根据欧洲及澳大拉西亚急性中风研究(ECASS)II标准定义溶栓相关的AHT。比较两

Neuroscience:患者发生卒中后,警惕出现学习功能障碍

认为学习能力支持卒中后的恢复和康复治疗。因此,学习障碍可能会减少恢复的潜力。这里,研究者提出假设,卒中幸存者存在反馈驱动内隐学习障碍。卒中幸存者30例和按照年龄配对的健康对照组21例,受试者学习分类任务,同时对亚组进行功能磁共振扫描(17卒中患者,10名对照患者)。卒中人员学习分类线索比对照组慢。奖励一个笑脸后,当重复这个线索时,卒中幸存者不太可能给出相同的反应。与对照组相比,脑卒中患者苍白球,丘

Clin Lab:卒中类型不同,血脂代谢不同

背景:越来越多的流行病学研究已经确定了血脂异常与动脉粥样硬化性卒中之间的关系密切。的确,脂类代谢在不同的卒中类型中存在差异。有关特定类型的缺血性卒中的危险因素的研究较少,尤其是,有关血脂异常的作用的证据较少。本研究旨在确定急性缺血性卒中类型和血脂水平的关系。方法:检测362例缺血性脑卒中患者和181例健康对照者血脂,包括TC、TG、LDL-C、HDL-C、ApoA、ApoB、ApoE水平和LP(a

JAMA Neurol:远程医疗对院前卒中患者的评估和治疗效果

背景:现场治疗处理团队的移动卒中治疗单元(MSTUs)包括可以提供溶栓的血管神经医师。这个单元可以高效利用资源,如果可以依赖远程医疗的话,可以减少对现场神经科医生的需要。

美国心脏病协会更新心脏病和卒中年度数据

美国心脏病协会(AHA)新发数据表明美健康行为干预与危险因素防控效果显著,10年心血管和卒中死亡率持续下降,但全球负担仍严重。

JAMA Neurol:小血管病存在与颅内动脉狭窄患者卒中发生风险增加无关

重要性:颅内动脉狭窄(ICAS)和小血管病(SVD)可以共存。有关于ICAS 与SVD共存的危险因素,及SVD对正在接受药物治疗的ICAS患者卒中再发的影响的研究较少。目标:调查SVD的危险因素以及SVD对ICAS患者卒中再发的影响。设计,设置和参与者:SAMMPRIS研究是一项前瞻性,多中心的临床试验,对其进行post-hoc分析。在451名受试者中,313(69.4%)名基线脑MRI显示SVD